gastrointestinal bleeding. Hemospray achieved immediate and short term hemostasis in all cases. However, rebleed is possible in less than 48 hours after.

**IDDF2019-ABS-0329**  
**EXPECTATION OF ASIA-PACIFIC PHYSICIANS AND PATIENTS TOWARDS IDEAL ERADICATION RATE OF ANTI-H. PYLORI REGIMENS**

1Yoen Young Chuah*, 2Deng Chyang Wu, 3Seng Kee Chuah, 4Yyh Chin Yang, 5Tzong Hsi Lee, 6Hong Zen Yeh, 7Chan Lin Chen, 8Yu Hwa Liu, 9Ping I Hsu, 10Ping Tung Christian Hospital, Taiwan; Kaohsiung Medical University Hospital, Taiwan; Kaohsiung Chang Gung Memorial Hospital, Taiwan; National Taiwan University Hospital, Taiwan; Far Eastern Memorial Hospital, Taiwan; Taichung Veterans General Hospital, Taiwan; Hualien Tzu Chi Medical Center, Taiwan; Shin Kong Wu Ho-Su Memorial Hospital, Taiwan; Kaohsiung Veterans General Hospital, Taiwan

10.1136/gutjnl-2019-IDDFabstracts.234

**Background** The aims of the study were to survey (1) the ideal eradication rate for anti-H. pylori regimens from the expectation of Asia-Pacific physicians and patients (2) to investigate the expectation gaps of ideal eradication rate between physicians and patients.

**Methods** A questionnaire was disseminated to physicians who attended the Asia-Pacific Digestive Week 2015 meeting. In addition, a questionnaire was disseminated to H. pylori-infected patients in Taiwan. Reported ideal eradication rates from the physicians and patients were collected and analyzed.

**Results** A total of 754 physicians and 973 patients participated in the survey. The ideal eradication rate for anti-H. pylori regimens anticipated by Asia Pacific physicians was 91.5%. Physicians from Malaysia had the highest expectation at 93.2%. The expectation of physicians and patients towards ideal eradication rate of anti-H. pylori regimens were 91.1% and 93.1% respectively in Taiwan. The expectation on ideal eradication rate among patients was higher than that of physicians (93.1% vs 91.1%, P<0.001).

**Conclusions** It is time for Asia-Pacific physicians to implement more efficacious ideal anti-H. pylori regimens to meet the expectations of their patients and themselves.

**IDDF2019-ABS-0331**  
**INTRALUMINAL BRACHYTHERAPY (ILBT) BOOST FOLLOWING CONCURRENT CHEMORADIATION IN PATIENTS OF INOPERABLE OESOPHAEGAL CANCER – A SINGLE INSTITUTE EXPERIENCE**

1Divya Khosla*, 2Rakesh Kapoor, 3Renu Madan, 4Sakshi Rana, 5Arjun Dinam, 6Ranjit Singh, 7Narendra Kumar, 8Kennan Persamy, 9Bushi Yadav, 10Suinder Rana, 11Rajesh Gupta. 1Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India; 2Department of Gastroenterology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India; 3Department of Surgical Gastroenterology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

10.1136/gutjnl-2019-IDDFabstracts.235

**Background** Definitive concurrent chemoradiation is the standard of care for patients with inoperable oesophageal cancer. Intraluminal brachytherapy (ILBT) given as boost following concurrent chemoradiation increases the dose to tumor with sparing of adjacent normal structures. The aim of the present study was to analyse the response to concurrent chemoradiation followed by ILBT as a boost in inoperable oesophageal cancer patients.

**Methods** Twenty-two patients of carcinoma of the middle and lower oesophagus were included in the study. All patients received external beam radiotherapy of 40 Gy in 20 fractions over 4 weeks with concomitant chemotherapy with weekly cisplatin and 5-fluorouracil. Barium swallow and upper gastrointestinal endoscopy were performed for response assessment at 2 weeks post chemoradiation. The dose of brachytherapy was two fractions of 6 Gy delivered one week apart. Universal plastic bougie was inserted and a margin of 2 cm was given to residual tumor in superior and inferior direction. The dose was prescribed at 8 mm from midline and treatment was delivered by a high dose rate 60Co source (figure 1). Response evaluation was done at 1 and at 3 months after treatment completion.

**Results** The patient and tumor characteristics are shown in table 1 (table 1). The treatment was well tolerated and all patients completed the prescribed course of therapy. The swallowing ability improved in all patients except one patient after a month of therapy. No patient developed grade 3 or higher toxicity. Dysphagia score at one month follow up was grade 1 in 10 patients and grade 2 in 3 patients. None of the patients had grade 3 or 4 dysphagia after treatment. The median follow-up was 11 months. Three patients had progression of disease with worsening of dysphagia. Four patients had dysphagia due to stricture which was relieved by endoscopic dilatation.

### Table 1 Patient and tumor characteristics (n=22)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age</td>
<td>59</td>
</tr>
<tr>
<td>Male</td>
<td>14</td>
</tr>
<tr>
<td>Female</td>
<td>8</td>
</tr>
<tr>
<td>Tumor length</td>
<td>7.05 cm</td>
</tr>
<tr>
<td>Median number of cycles</td>
<td>3</td>
</tr>
</tbody>
</table>

**Abstract IDDF2019-ABS-0331**  
**Figure 1** Isodose curves